1,827 results on '"Merkel, Peter A"'
Search Results
302. Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study
303. Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features
304. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
305. LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
306. LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
307. Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma
308. Harnessing health plan enrollee data to boost membership in patient-powered research networks
309. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial
310. Clinical associations of renal involvement in ANCA-associated vasculitis
311. A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
312. Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort
313. Alpha1-antitrypsin deficiency–related alleles Z and S and the risk of Wegenerʼs granulomatosis
314. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis
315. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review
316. Giant Cell Arteritis
317. Overview of Vasculitis
318. CONTRIBUTORS
319. Assessment of damage in vasculitis: expert ratings of damage
320. Macrophage migration inhibitory factor (MIF) gene polymorphism in Wegenerʼs granulomatosis (WG): N4
321. Alpha 1-antitrypsin deficiency and the risk for Wegenerʼs granulomatosis: N1
322. Damage caused by Wegenerʼs granulomatosis: data from a multicenter longitudinal cohort: K6
323. Morbidity and mortality of Wegenerʼs granulomatosis: data from a current multicenter longitudinal cohort: K12
324. Angiopoietin-2 as a biomarker in ANCA-associated vasculitis: E2
325. Trigeminal trophic syndrome: a mimic of ANCA-associated vasculitis: D37
326. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial
327. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
328. Medication Interruptions and Subsequent Disease Flares During the COVID‐19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease.
329. Core Set of Domains for Outcome Measures in Behçet's Syndrome.
330. Additional file 4 of A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
331. Survey – Supplemental material for Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma
332. Additional file 3 of A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
333. Additional file 2 of A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
334. Additional file 1 of A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
335. Additional file 1 of Harnessing health plan enrollee data to boost membership in patient-powered research networks
336. Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegenerʼs Granulomatosis
337. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Type I Collagen Treatment in Patients With Diffuse Cutaneous Systemic Sclerosis: I. Oral Type I Collagen Does Not Improve Skin in All Patients, But May Improve Skin in Late-Phase Disease
338. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I
339. Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis
340. Detection of circulating PR3-specific B cells in patients with active ANCA-associated vasculitis
341. Treatment Response Criteria For ANCA-Associated Vascultis: Results of a Scoping Review
342. The frequency and severity of patient-reported symptoms in giant cell arteritis
343. TREATMENT RESPONSE CRITERIA FOR ANCA-ASSOCIATED VASCULITIS: RESULTS OF A SCOPING REVIEW
344. Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
345. Adjunctive Methotrexate for Treatment of Giant Cell Arteritis: An Individual Patient Data Meta-Analysis
346. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
347. Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial
348. Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
349. 10. Development of novel reactive barrier technologies at the SAFIRA test site, Bitterfeld
350. Myofibroblasts and Hyalinized Collagen as Markers of Skin Disease in Systemic Sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.